StockNews.AI
NAGE
StockNews.AI
112 days

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

1. NAGE appoints Dr. Pinchas Cohen to its Scientific Advisory Board. 2. Cohen's expertise in aging may enhance NAGE's innovation strategy.

2m saved
Insight
Article

FAQ

Why Bullish?

The appointment of a renowned expert like Dr. Cohen can drive investor confidence and innovation. Historical examples show that leadership changes drive stock prices positively, particularly in biotech sectors.

How important is it?

The hiring of a leading expert enhances NAGE’s credibility and potential for breakthroughs, likely increasing stock attraction. Investing in leadership with strong industry links tends to correlate with heightened market interest.

Why Long Term?

Cohen’s expertise in healthy aging aligns with NAGE's long-term strategy, likely impacting future research and product development positively. Previous biotech appointments have shown sustained price increases over extended periods due to innovative advancements.

Related Companies

CHRABMRNREGN
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB). Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of.

Related News